Exchange: NASDAQ·Updated 08:51 PM EDT
DXCM logo

DXCMDexcom Inc

$80.00
$0.60
(0.80%)
Today
Closed $74.54
$5.46
(7.33%)
Overnight
Reported EarningsJul 30
Mkt Cap$28.99B
Vol5.65M
News
all
press releases
DexCom (DXCM) Q2 Earnings and Revenues Top Estimates
DexCom (DXCM) delivered earnings and revenue surprises of +14.75% and +1.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Dexcom Reports Second Quarter 2026 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights: Revenue grew 13% year-over-year to $1.308 billion on a reported basis and 12% year-over-year on an organic1 basis. U.S. revenue grew 11% and...
Business Wire
Philips Q2 Earnings and Revenues Increase Year over Year, Shares Down
PHG lifts its 2026 profit and free cash flow outlook after Q2 earnings increase on higher sales, productivity gains and a U.S. tariff refund benefit.
Zacks
Watch These 4 Medical Product Stocks for Q2 Earnings: Beat or Miss?
Medical product makers face Q2 margin pressure from tariffs and inflation even as demand stays strong. See which earnings reports could surprise.
Zacks
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, July 29, 2026 Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We...
PR Newswire
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
Abbott Rides Key Diabetes, Oncology and Heart Care Innovation Trends
ABT is expanding across diabetes care, oncology diagnostics and heart devices, with new launches and acquisitions creating multiple growth paths to watch.
Zacks
DXCM Q2 Results Likely to Reflect Strong G7 & Reimbursement Expansion
DXCM's Q2 results may reflect strong G7 15 Day adoption, broader reimbursement, and expanding CGM demand as investors watch for continued double-digit revenue growth.
Zacks
Is Abbott Stock Attractive After Its Earnings and Guidance Update?
ABT's earnings beat and higher profit outlook strengthen its case, but can growth in devices and diagnostics overcome valuation and acquisition concerns?
Zacks
DexCom (DXCM) Earnings Expected to Grow: Should You Buy?
DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
<
1
2
>

Advertisement|Remove ads.